Kura Oncology

159 articles with Kura Oncology

• Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

  3/14/2023

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando from April 14-19, 2023.

• Kura Oncology to Participate in Upcoming Investor Conferences

  3/1/2023

  Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences.

• Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

  2/23/2023

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2022 financial results and provided a corporate update.

• Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

  2/16/2023

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023.

• Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

  2/9/2023

  Kura Oncology, Inc. today announced that the first patients have been dosed in its KOMET-001 Phase 2 registration-directed trial of ziftomenib, the Company’s novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).

• Kura Oncology to Participate in SVB Securities Global Biopharma Conference

  2/7/2023

  Kura Oncology, Inc. today announced its participation in the virtual SVB Securities Global Biopharma Conference.

• Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

  1/24/2023

  Kura Oncology, Inc. today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors.

• Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

  12/10/2022

  Kura Oncology, Inc. announced updated clinical data from KOMET-001, a Phase 1/2 trial of the Company’s potent and selective menin inhibitor, ziftomenib, including an encouraging safety and tolerability profile and clinical activity in patients with relapsed/refractory acute myeloid leukemia.

• Kura Oncology to Host Investor Event on December 10, 2022In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New Orleans

  12/1/2022

  Kura Oncology, Inc. today announced that it will host an investor event featuring members of the Kura management team and investigators from KOMET-001, a Phase 1/2 clinical trial of ziftomenib, the Company’s potent and selective menin inhibitor.

• Kura Oncology to Participate in Two Upcoming Investor Conferences - November 22, 2022

  11/22/2022

  Kura Oncology, Inc., announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.

• Kura Oncology Reports Third Quarter 2022 Financial Results

  11/3/2022

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2022 financial results and provided a corporate update.

• Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

  11/3/2022

  Kura Oncology, Inc. announced that four abstracts highlighting ziftomenib, the Company’s potent and selective menin inhibitor, have been accepted for presentation at the upcoming American Society of Hematology Annual Meeting, to be held in New Orleans from December 10-13, 2022.

• Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

  11/3/2022

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced a $25 million equity investment from Bristol Myers Squibb and a term loan facility with access to up to $125 million from Hercules Capital, Inc.

• Kura Oncology to Participate in Two Upcoming November 2022 Investor Conferences

  11/2/2022

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.

• Kura Oncology to Report Third Quarter 2022 Financial Results  

  10/27/2022

  Kura Oncology, Inc. today announced that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022.

• Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

  10/26/2022

  Kura Oncology, Inc. today reported proof of mechanism in KURRENT-HN, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).

• Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

  9/1/2022

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the H.C. Wainwright 24th Annual Global Investment Conference.

• Kura Oncology Reports Second Quarter 2022 Financial Results

  8/3/2022

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported second quarter 2022 financial results and provided a corporate update.

• Kura Oncology to Report Second Quarter 2022 Financial Results

  7/27/2022

  Kura Oncology, Inc. today announced that it will report second quarter 2022 financial results after the close of U.S. financial markets on Wednesday, August 3, 2022.

• Kura Oncology to Participate in Three Upcoming Investor Conferences in June 2022

  5/26/2022

  Kura Oncology, Inc. announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences: